GRI

MHRA approves polihexanide to treat acanthamoeba keratitis

News Healthcare & Pharma Law & Policy Updates
Date: 23rd May, 2025 Source: Medicines and Healthcare products Regulatory Agency (MHRA) Country: United Kingdom Original Source

Brief

On 15 May 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) issued an update regarding MHRA approves polihexanide to treat acanthamoeba keratitis. The approval was granted through the International Recognition Procedure (IRP), allowing for targeted assessment of applications.

This content is restricted.

Highlights content goes here...

This content is restricted.

Medicines and Healthcare products Regulatory Agency (MHRA)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
Related Documents
32 million euros for patent calls+, drawings+ and brands+ from 2025
Date: 2nd Sep, 2025 Source: Italian Patent and Trademark Office Country: Italy
News Intellectual property Law & Policy Updates
Increased risks identified with Profemur cobalt chrome modular neck hip replacements
Date: 4th Sep, 2025 Source: Medicines and Healthcare products Regulatory Agency (MHRA) Country: United Kingdom
News Healthcare & Pharma Guidance
CFTC Issues Policy Statement on Referrals for Potential Criminal Enforcement
Date: 5th Sep, 2025 Source: Commodity Futures Trading Commission (CFTC) Country: USA
News Corporate Finance & M&A Law & Policy Updates

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Click here

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
  • Designed for Growing Compliance Teams
$125 / month OR $1250 / year
Features
  • • Coverage for 20 jurisdictions
  • • Monitoring from 500+ regulatory authorities
  • • AI compliance summaries
  • • RaDa.ai : Single-Role
Best for: Researchers, Legal professionals, Academics
Subscribe Now
Enterprise Plan
  • Perfect for Global Enterprises
Contact for Pricing
Features
  • • Custom jurisdictional coverage
  • • Custom monitoring of regulatory authorities
  • • RaDa.ai : Customizable multi-role
  • • Custom reporting and dashboard capabilities
  • • API access for seamless integration
Best for: Law Firms, Corporations, Government Bodies
Contact Sales